Making medicines evergreen

Another loophole exploited by the drug industry

BMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f354 (Published 22 January 2013)
Cite this as: BMJ 2013;346:f354

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Martin D Brunet, general practitioner1
  1. 1Binscombe Medical Centre, Godalming GU7 3PR, UK
  1. martin{at}binscombe.net

Hitchings and colleagues’ excellent analysis of the methods used by drug companies to maximise profits omitted a new tactic that has resulted in £46m (€55.5m; $74m) additional annual costs to the NHS.1 It exploits the fact that the price of generic drugs is not negotiated with the Department of Health because market forces are meant to keep prices …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL